BREAKING
Protagonist Therapeutics Jumps 7.0% in Broad Rally 2 hours ago Valaris Limited Drops 6.7% in Broad Selloff 3 hours ago Talos Energy Inc. Drops 6.2% Amid Sector-Wide Selling 4 hours ago Northern Oil and Gas, Inc. Drops 5.2% in Broad Selloff 4 hours ago Bank7 Corp. Tops Q1 Forecasts With $1.25 EPS, 20.2% Above Consensus 4 hours ago JetBlue Airways Corporation Surges 15.1% in Broad Rally 5 hours ago Celanese Corporation Shares Dropping 5.5% 5 hours ago Akamai Technologies, Inc. Shares Dropping 5.3% 5 hours ago Amazon.com, Inc. (AMZN) Jumps 5.2% to $232.68 5 hours ago Boot Barn Holdings, Inc. Shares Jumping 5.2% 5 hours ago Protagonist Therapeutics Jumps 7.0% in Broad Rally 2 hours ago Valaris Limited Drops 6.7% in Broad Selloff 3 hours ago Talos Energy Inc. Drops 6.2% Amid Sector-Wide Selling 4 hours ago Northern Oil and Gas, Inc. Drops 5.2% in Broad Selloff 4 hours ago Bank7 Corp. Tops Q1 Forecasts With $1.25 EPS, 20.2% Above Consensus 4 hours ago JetBlue Airways Corporation Surges 15.1% in Broad Rally 5 hours ago Celanese Corporation Shares Dropping 5.5% 5 hours ago Akamai Technologies, Inc. Shares Dropping 5.3% 5 hours ago Amazon.com, Inc. (AMZN) Jumps 5.2% to $232.68 5 hours ago Boot Barn Holdings, Inc. Shares Jumping 5.2% 5 hours ago
ADVERTISEMENT
AlphaGraphs

AngioDynamics second-quarter results beat market estimates

AngioDynamics posted second-quarter earnings on Friday, Jan. 4. before trading hours. Net sales for the period inched 5.5% to $91.5 million, with diluted net profit jumping to $0.06 per share — growing six-fold from last year’s $0.01 per share. Net income soared to $2.14 million, up from $249,000. The market expected earnings of $0.20 per share on […]

January 4, 2019 2 min read
AlphaGraphs

AngioDynamics posted second-quarter earnings on Friday, Jan. 4. before trading hours. Net sales for the period inched 5.5% to $91.5 million, with diluted net profit jumping to $0.06 per share — growing six-fold from last year’s $0.01 per share. Net income soared to $2.14 million, up from $249,000. The market expected earnings of $0.20 per share on […]

AngioDynamics posted second-quarter earnings on Friday, Jan. 4. before trading hours. Net sales for the period inched 5.5% to $91.5 million, with diluted net profit jumping to $0.06 per share — growing six-fold from last year’s $0.01 per share. Net income soared to $2.14 million, up from $249,000.

The market expected earnings of $0.20 per share on revenue of $88.90 million. Both top line and bottom line exceeded the consensus.

Gross margin for the quarter soared 440 basis points year over year to 53.7%, while cash provided by operations was $13.0 million. Capital expenditures was $0.7 million for the period.

US net sales in the quarter rose 5.2% to $71.9 million while International net sales grow 6.6% to $19.6 million.

AngioDynamics second quarter 2019 Earnings Infographic

Back in September, AngioDynamics announced that it would acquire privately held medical diagnostic and device company RadiaDyne. The latter designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

This deal added to AngioDynamics’ portfolio RadiaDyne’s early-stage, proprietary real-time radiation dose monitoring platform and other market-leading oncology solutions.

“The acquisition of RadiaDyne, combined with our recent BioSentry asset purchase, delivers on our commitment to build a world-class oncology portfolio,” said CEO Jim Clemmer.

In September of 2018, RadiaDyne’s trailing 12-months revenues exceeded $6 million. The acquisition was then expected to be neutral to earnings on an adjusted basis.

In the previously reported first-quarter, AngioDynamics missed analyst estimates with earnings of $0.16 per share, sending shares down then. The company had reported flat revenues of $85.3 million over last year, hurt by 6% slump in oncology product sales. it also had a one-time impact in the quarter due to its transition from Acculis to Solero product line.

AngioDynamics has been seeing US sales dipping in the past two quarters, despite international sales picking up. Last quarter, it even had to pay $12.7 million due to the legal allegations faced with the Justice Department.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

ADVERTISEMENT